Skip to main content
21 January 2021
Last updated:
Wednesday 20 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Positive data for candidate heart treatment

Monday 16 November 2020
Country

Germany

Germany-based Cardior Pharmaceuticals GmbH has announced positive results from a Phase 1b study of its lead compound CDR132L, an antisense oligonucleotide, for heart failure.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Clinical Research
Company News

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Richard Francis named CEO of Purespring
Tuesday January 19 2021
Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021
Sam Herbert becomes COO at Clinigen
Wednesday January 6 2021
Wolfgang Baiker becomes CEO at Adrenomed
Wednesday January 6 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.